The pharmaceutical corridors are buzzing with a development that sounds more like a high-stakes corporate thriller than a standard financial result. Novartis India Limited has just dropped its Q4 and full-year FY26 results, but the numbers are playing second fiddle to a massive structural earthquake. After decades of Swiss dominance, the parent company, Novartis AG, has pulled the trigger on a complete exit, signing a Share Purchase Agreement (SPA) on February 19, 2026, to sell its entire 70.68% stake to a consortium led by ChrysCapital.
While the top line shows a curious resilience with sales moving to ₹910 million in the final quarter, the real story is hidden in the valuation gap. An open offer has been triggered at ₹860.64 per share, a figure that sits uncomfortably below the recent market highs, creating a unique arbitrage or “trap” scenario for the uninitiated. With net profits for the year touching ₹932 million, the company is maintaining its lean, trading-heavy profile while the ownership transition looms like a giant shadow.
The most glaring red flag? The board has recommended Zero Dividend for FY26, a sharp and painful pivot from the ₹25 per share handed out just a year ago. Is the cash being hoarded for the new masters, or is the well running dry just as the Swiss pack their bags?
Introduction
Novartis India is not your typical pharma manufacturer. In fact, if you look closely at its operational DNA, it is more of a high-end distribution engine. The company primarily imports breakthrough medicines from its global parent’s massive chest of intellectual property and wholesales them across the Indian landscape. We are talking about critical therapeutic areas: Pain Management (Voveran), Transplantation Immunology (Simulect, Sandimmun), and Neurosciences (Tegrital).
For years, this has been a “royalty and trading” play. The company doesn’t spend billions on R&D in India; it leverages the parent’s $45 billion global revenue muscle to bring “New Chemical Entities” to the local market. However, the dynamics changed when they entered a massive distribution pact with Dr. Reddy’s Laboratories in 2022. Suddenly, Novartis India was no longer just selling pills; it was managing a brand portfolio while someone else handled the heavy lifting of the field force.
Now, as we stand in May 2026, the company is at a crossroads. The Managing Director, Sanjay Murdeshwar, has exited, and the Swiss parent is handing over the keys to WaveRise Investments, ChrysCapital, and Two Infinity Partners. This isn’t just a change in the letterhead; it is a fundamental shift from a multinational subsidiary to a private equity-backed enterprise.
Business Model – WTF Do They Even Do?
To understand Novartis India, you have to stop thinking about lab coats and test tubes and start thinking about high-margin logistics. They are essentially the “Exclusive VIP Pass” for Swiss medicine in India. 99% of their revenue comes from the sale of traded goods. They buy from the parent, mark it up, and sell it here.
They focus on “Life or Death” segments. You don’t just “stop” taking immunosuppressants after an organ transplant because the price went up. This gives them immense pricing power, but that power is constantly checked by the Indian Government’s National List of Essential Medicines (NLEM). When the government slashes prices, Novartis feels the heat instantly, as seen in their 12% revenue dip back in FY24.
The “WTF” moment in their business model is the Dr. Reddy’s Agreement. They basically outsourced their sales team for the Voveran and Calcium range to Dr. Reddy’s. Why? Because maintaining a massive army of medical reps is expensive
